Plain-English translation of NCT07192614 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new medication called in men with advanced prostate cancer that has spread to other parts of the body. The medication works differently than typical treatments — it's designed to wake up your immune system and help it recognize and attack cancer cells. Researchers want to find the safest and most effective dose, and to understand how the medication moves through your body and how well it works.
Many men with advanced prostate cancer eventually develop resistance to hormone-blocking therapies, meaning their cancer keeps growing even with standard treatment. This medication represents a new approach — using the immune system as a weapon — and doctors hope it may help patients whose cancers have stopped responding to other options.
You likely qualify if…
You likely don't qualify if…
The study has two main phases. First, researchers will test increasing doses of the medication in small groups to find the safest dose (dose escalation). Then, a larger group will receive the recommended dose to learn how well it works (dose expansion). You would receive the medication through injections or infusions at a hospital or clinic, attend regular visits for blood tests and imaging to monitor your cancer and check for side effects, and possibly have additional biopsies. The study involves visits over several months as doctors watch how your body responds to the treatment.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
United States